Suppr超能文献

患者报告结局和吸入器操作错误在哮喘和 COPD 控制中的作用的叙述性综述。

Narrative Review of the Role of Patient-Reported Outcomes and Inhaler Handling Errors in the Control of Asthma and COPD.

机构信息

Primary Care Physician, Luis Vives Health Center, Alcala de Henares, Madrid, Spain.

Primary Care Physician, Henares Azuqueca Health Center, Guadalajara, Spain.

出版信息

Curr Allergy Asthma Rep. 2022 Nov;22(11):151-161. doi: 10.1007/s11882-022-01041-2. Epub 2022 Sep 10.

Abstract

PURPOSE OF REVIEW

Asthma and chronic obstructive pulmonary disease (COPD) are chronic respiratory diseases that remain uncontrolled in many patients, despite the wide range of therapeutic options available. This review analyzes the available clinical evidence on 3 budesonide/formoterol DPI devices, Spiromax, Turbuhaler, and Easyhaler, in terms of patient-reported outcomes (PROs), inhaler errors, and asthma and COPD control.

RECENT FINDINGS

The effectiveness of dry powder inhalers (DPI) depends largely on the device and the patient's inhaler technique. Equally important are the patient's perception of the inhaler and adherence. Given the high burden of these diseases, it is important that efforts be made to select the best DPI for each patient and to analyze the impact of these variables to help improve the health and quality of life of our patients. This review provides a comprehensive overview of the present knowledge about PROs, inhaler handling errors, and asthma and COPD control achieved by Spiromax, Turbuhaler, and Easyhaler.

摘要

目的综述

尽管有多种治疗选择,但哮喘和慢性阻塞性肺疾病(COPD)仍然是许多患者无法控制的慢性呼吸道疾病。本综述分析了现有关于布地奈德/福莫特罗三种干粉吸入器(DPI),即 Spiromax、Turbuhaler 和 Easyhaler 的临床证据,内容涉及患者报告的结局(PRO)、吸入器错误以及哮喘和 COPD 的控制情况。

最新发现

干粉吸入器(DPI)的有效性在很大程度上取决于设备和患者的吸入器技术。同样重要的是患者对吸入器的感知和依从性。鉴于这些疾病的负担很重,重要的是要努力为每个患者选择最佳的 DPI,并分析这些变量的影响,以帮助改善我们患者的健康和生活质量。本综述全面概述了 Spiromax、Turbuhaler 和 Easyhaler 在患者报告的结局、吸入器操作错误以及哮喘和 COPD 控制方面的现有知识。

相似文献

1
Narrative Review of the Role of Patient-Reported Outcomes and Inhaler Handling Errors in the Control of Asthma and COPD.
Curr Allergy Asthma Rep. 2022 Nov;22(11):151-161. doi: 10.1007/s11882-022-01041-2. Epub 2022 Sep 10.
6
Onset of action of budesonide/formoterol Spiromax(®) compared with budesonide/formoterol Turbuhaler(®) in patients with COPD.
Pulm Pharmacol Ther. 2016 Aug;39:48-53. doi: 10.1016/j.pupt.2016.06.006. Epub 2016 Jun 22.
9
The dry powder inhaler features of the Easyhaler that benefit the management of patients.
Expert Rev Respir Med. 2020 Apr;14(4):345-351. doi: 10.1080/17476348.2020.1721286. Epub 2020 Feb 4.

本文引用的文献

4
Predictive value of control of COPD for risk of exacerbations: An international, prospective study.
Respirology. 2020 Nov;25(11):1136-1143. doi: 10.1111/resp.13811. Epub 2020 Apr 6.
6
The dry powder inhaler features of the Easyhaler that benefit the management of patients.
Expert Rev Respir Med. 2020 Apr;14(4):345-351. doi: 10.1080/17476348.2020.1721286. Epub 2020 Feb 4.
7
Understanding Dry Powder Inhalers: Key Technical and Patient Preference Attributes.
Adv Ther. 2019 Oct;36(10):2547-2557. doi: 10.1007/s12325-019-01066-6. Epub 2019 Sep 2.
10
The importance of patient-reported outcomes in clinical trials and strategies for future optimization.
Patient Relat Outcome Meas. 2018 Nov 1;9:353-367. doi: 10.2147/PROM.S156279. eCollection 2018.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验